Polymorphisms in tumour necrosis factor and adhesion molecule genes in patients with inflammatory bowel disease: Associations with HLA-DR and -DQ alleles and subclinical markers

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 10, 1999, Pages 1025-1032

  Hirv, K ^a,b   Seyfarth, M ^a,b   Uibo, R ^a,b   Kull, K ^a,b   Salupere, R ^a,b   Latza, U ^a,b   Rink, L ^a,b,c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF TARTU   (Estonia)

^c Inst of Immunol and Transfus Med   (Germany)

Author keywords

Adhesion molecules; Antineutrophil cytoplasmic antibody; HLA class II genes; Inflammatory bowel disease; Polymorphism; Tumour necrosis factor

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENTERITIS; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HLA TYPING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; ULCERATIVE COLITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; COLITIS, ULCERATIVE; E-SELECTIN; ESTONIA; FEMALE; GENES, MHC CLASS II; HISTOCOMPATIBILITY TESTING; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR ADHESION MOLECULE-1; L-SELECTIN; MALE; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032693411     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655299750025147     Document Type: Article

References (47)

1. 1. Satsangi J, Jewell DP, Rosenberg WMC, Bell JI. Genetics of inflammatory bowel disease. Gut 1994;35:696-700.
2. 2. Satsangi J, Jewell DP, Bell JI. The genetics of inflammatory bowel disease. Gut 1997;40:572-4.
3. 3. Koutroubakis I, Manousos ON, Meuwissen SGM, Peña AS. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996;43:381-93.
4. 4. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:5S-11S.
5. 5. Asakura H, Tsuchiya M, Aiso S, Watanabe M, Kobayashi K, Hibi T, et al. Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis. Gastroenterology 1982;82: 413-8.
6. 6. Yang H, Rotter JI, Toyoda H, Landers C, Tyan D, McElree CK, et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993;92:1080-4.
7. 7. Bouma G, Oudkerk Pool M, Crusius JBA, Schreuder GMT, Hellemans HPR, Meijer BUGA, et al. Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD). Clin Exp Immunol 1997;109:175-9.
8. 8. Forcione DG, Sands B, Isselbacher KJ, Rustgi A, Podolsky DK, Pillai S. An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele. Proc Natl Acad Sci 1996;93:5094-8.
9. 9. Cariappa A, Sands B, Forcione D, Finkelstein D, Podolsky DK, Pillai S. Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease. Gut 1998;43:210-5.
10. 10. Toyoda H, Wang SJ, Yang HY, Redford A, Magalong D, Tyan D, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-8.
11. 11. Reinshagen M, Loeliger C, Kuehnl P, Weiss U, Manfras BJ, Adler G, et al. HLA class II gene frequencies in Crohn's disease: a population based analysis in Germany. Gut 1996;38:538-42.
12. 12. Danzé PM, Colombel JF, Jacquot S, Loste MN, Heresbach D, Ategbo S, et al. Association of HLA class II genes with susceptibility to Crohn's disease. Gut 1996;39:69-72.
13. 13. Rink L, Kirchner H. Recent progress in the tumor necrosis factor-α field. Int Arch Allergy Immunol 1996;111:199-209.
14. 14. Bouma G, Crusius JBA, Oudkerk Pool M, Kolkman JJ, Blomberg BME, Kostense PJ, et al. Secretion of tumour necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-63.
15. 15. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LBA, Duff GW. An allelic polymorphism within the human tumour necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-60.
16. 16. Targan SR, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
17. 17. Van Deventer SJH. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
18. 18. Springer TA. Traffic signals for lymphocyte recirculation and leucocyte emigration: the multistep paradigm. Cell 1994;76: 301-14.
19. 19. Brown EJ. Adhesive interactions in the immune system. Trends Cell Biol 1997;7:289-95.
20. 20. Yang H, Vora DK, Targan SR, Toyoda H, Beaudet AL, Rotter JI. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology 1995;109:440-8.
21. 21. Orholm M, Iselius L, Sørensen TIA, Munkholm P, Langholz E, Binder V. Investigation of inheritance of chronic inflammatory bowel diseases by complex segregation analysis. Br Med J 1993;306:20-4.
22. 22. Pavli P, Cavanaugh J, Grimm M. Inflammatory bowel disease: germs or genes? Lancet 1996;347:1198.
23. 23. Yang H. Analysis of ICAM-1 gene polymorphism in immunologic subsets of inflammatory bowel disease. Exp Clin Immunogenet 1997;14:214-25.
24. 24. Shanahan F, Duerr RH, Rotter JI, Yang H, Sutherland LR, McElree C, et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992;103:456-61.
25. 25. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Anti-neutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995;90:740-7.
26. 26. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 1991;100;1590-6.
27. 27. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24 Suppl 170:2-6.
28. 28. Wiik A, Rasmussen N, Wieslander J. Methods to detect autoantibodies to neutrophilic granulocytes. In: Van Venrooij WJ, Maini RN, editors. Manual of biological markers of disease. Dordrecht: Kluwer Academic Publisher; 1993. p. 1-14.
29. 29. Wilson AG, di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNFα) gene detectable by NcoI restriction of PCR product. Hum Mol Gen 1992;1:353.
30. 30. Stüber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism wilhin the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with sèvere sepsis. Crit Care Med 1996;24:381-4.
31. 31. Vora DK, Rosenbloom CL, Beaudet AL, Cottingham RW. Polymorphism and linkage analysis for ICAM-1 and the selectin gene cluster. Genomics 1994;21:473-7.
32. 32. Wenzel K, Ernst M, Rohde K, Bauman G, Speer A. DNA polymorphisms in adhesion molecule genes - a new risk factor for early atherosclerosis. Hum Genet 1996;97:15-20.
33. 33. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994;43:18-27.
34. 34. Satsangi J, Welsh KI, Brunce M, Julier C, Farrant JM, Bell JI, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347:1212-7.
35. 35. Salupere R, Salupere V. Hepatobiliary complications of ulcerative colitis. A study on Estonian patients. Gut 1995;35:A30.
36. 36. Salupere R, Salupere V. Epidemiology of inflammatory bowel diseases in Tartu county, Estonia. In: 10th Congress of Gastroenterology. Abstracts II. 1994; Los Angeles; p. A535.
37. 37. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut 1996;39:690-7.
38. 38. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994;107:532-6.
39. 39. Duerr RH, Neigut DA. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup. Gastroenterology 1995;108:423-7.
40. 40. Satsangi J, Landers CJ, Welsh KI, Koss K, Targan S, Jewell DP. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 1998;4:18-26.
41. 41. Masuda H, Nakamura Y, Tanaka T, Hayakawa S. Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am J Gastroenterol 1994;89:1957-62.
42. 42. Concha EGD, Fernandez-Arquero M, Santa-Cruz S, Lopez-Nava G, Figueredo MA, Diaz-Rubio M, et al. Positive and negative associations of distinct HLA-DR2 subtypes with ulcerative colitis (UC). Clin Exp Immunol 1997;108:392-5.
43. 43. Heresbach D, Colombel F, Danze PM, Semana G. The HLA DRB1*0301-DQB1*0201 haplotype confers protection against inflammatory bowel disease. Am J Gastroenterol 1996;91:1060.
44. 44. Mansfield JC, Holden H, Tarlow JK, diGiovine FS, McDowell TL, Wilson AG, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-42.
45. 45. Louis E, Satsangi J, Roussomoustakaki M, Parkes M, Fanning G, Welsh K, et al. Cytokine gene polymorphisms in inflammatory bowel disease. Gut 1996;39:705-10.
46. 46. Roussomoustakaki M, Satsangi J, Welsh K, Louis E, Fanning G, Targan S, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997;112: 1845-53.
47. 47. Bouma G, Poen AC, García-González MA, Schreuder GMT, Felt-Bersma RJF, Meuwissen SGM, et al. HLA-DRB1*03, but not the TNFA-308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. Immunogenetics 1998;47:451-5.